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Introduction:   
 
Vascular targeted photodynamic therapy (VTP) with WST11 (TOOKAD® Soluble; 
STEBA Biotech, Luxembourg) is a promising new form of tissue ablation that may be 
used therapeutically for localized prostate cancer (PCa).  To study dosing parameters and 
associated treatment effects we undertook a prospective multicenter phase I/II trial of 
WST11 VTP for treatment of PCa 
 
Methods: 
 
30 men with unilateral, low volume, Gleason 3+3 PCa were enrolled at 5 centers 
following local IRB approval. Light energy, fiber number, and WST11 dose were 
escalated to identify optimal dosing parameters for VTP hemiablation. Necrosis extent 
was assessed on one week post-treatment MRI and 6 month biopsy. PSA, light dose 
index (LDI -defined as sum of fiber length/ desired treatment volume), toxicity, and 
quality of life parameters were recorded. 
 
Results: 
 
Following dose escalation, 21 men received optimal dosing of 4 mg/kg WST11 200 J 
energy.  A correlation was observed between LDI and tissue necrosis extent.  On post-
treatment biopsy, residual PCa was found in the treated lobe in 10 men, untreated lobe in 
4, and both lobes in 1.  When LDI≥1, at optimal dosing, (n=15), 73.3% had a negative 
biopsy in the treated lobe.  Six men undergoing retreatment, with optimal dose and LDI 
≥, had negative post-treatment biopsy.  Minimal effects on urinary, sexual function, and 
overall quality of life, were observed.  
 
Conclusions: 
 
Hemiablation of the prostate with WST11 VTP was well-tolerated and resulted in 
negative biopsy in the treated lobe for the majority of men. Dosing parameters and LDI 
appear related to tissue response as determined by MRI and biopsy. These parameters 
may serve as the basis for further prospective studies.   
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Introduction: 
 
In recent years, there has been a growing interest in tissue ablative strategies for focal 
therapy for localized prostate cancer (PCa)1–3 .  While early results of limited clinical 
trials have been promising, several obstacles remain before widespread adoption4.  In 
addition to a lack of long-term oncologic outcomes, short-term challenges in trial design 
persist, including candidate selection, method of treatment guidance, optimal energy 
source, and appropriate endpoints for follow-up5,1,3.Several energy sources have been 
tested in the prostate, demonstrating variable outcomes in local tissue destruction and 
tolerability6–8 , but there is limited data on the utilization of treatment planning and image 
correlation for evaluation of tissue necrosis9–12. 
 
One well-studied and proven form of soft tissue ablation is photodynamic therapy (PDT), 
which refers to tissue destruction created by the interaction of a specific wavelength of 
light with a photosensitive agent 9,13,14. Several advantages of PDT have been recognized, 
including lack of reliance on thermal energy dispersion or heat-sink effect 15.  WST11 
(TOOKAD® Soluble; STEBA Biotech, Luxembourg) is a recently described 
photodynamic agent that is retained in the vascular compartment, and mediates ablation 
through localized generation of oxygen free-radicals, resulting in vascular thrombosis and 
local cellular apoptosis 16–19. We undertook a prospective phase I/II multicenter trial of 
WST11 mediated vascular-targeted PDT (VTP) for the focal ablation of PCa. 
Methods: 
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Study Design 
This was a multi-center phase I/II, non-randomised, open-label, trial conducted within 5 
centers in the United States (ClinicalTrials.gov Identifier: NCT0094681).  Following 
approval by local institutional review boards, 30 men with serum PSA ≤ 10 ng/ml, 
clinical stage T1c/T2a, unilateral PCa demonstrated on a minimum 12 core transrectal 
prostate biopsy (PBx), who had been offered but refused traditional therapy, were 
enrolled.   Men were excluded if biopsy Gleason score > 3+3, > 50% of sampled cores 
positive, bilateral disease, any core with cancer length > 5 mm, current PCa treatment, 
hormonal deprivation (excluding 5-alpha reductase inhibitors) or supplementation within 
6 months, or previous TURP. 
 
The primary objective of the study was to define the optimal drug and light dosage 
necessary to achieve negative biopsy in the treated lobe, through sequential escalation of 
drug dose, light fiber number, and energy, and to determine the safety and tolerability of 
WST11-mediated VTP.  Secondary outcomes included quality of life, drug 
pharmacokinetics, and pharmacodynamics.  
 
Treatment Planning 
Included men underwent multiparametric magnetic resonance imaging (mpMRI), 
centrally reviewed by an external committee, to determine necessary tissue volume to be 
treated to achieve hemi-ablation of the cancer-bearing lobe; to plan the number, length 
and position of light fibers to be utilized in treatment; to identify obvious radiographic 
presence of extra-capsular disease; but not for cancer diagnosis or localization.  
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Treatment and Follow-up: 
 
Treatment consisted of a unilateral hemi-ablation of the affected lobe.  The procedure, 
performed using general anesthesia, has been previously described in detail 10,14,15  In 
brief, VTP consisted of a single, 10 minute IV administration of the designated dose of 
WST11 followed immediately by a 20 minute light exposure interval.  Light activation 
was delivered through transperineal interstitial optical fibers, placed prior to IV WST-11 
administration under TRUS guidance in accordance with a previously devised mpMRI-
based treatment plan. Laser light at 753 nm was delivered the designated energy level, 
using a multichannel diode laser (V-Gen Electro Optics Ltd, Israel, model 8CH-753 Mk 
II).  
 
The pre-defined dose escalation scheme, not segregated by study site, consisted of either 
2, 4, or 6 mg/kg WST11 activated with 200 or 300 J/cm light in a 3 + 3 dose escalation 
design to determine the maximum tolerated dose (MTD). The decision to escalate to 
subsequent drug and/or light dose was determined by an independent data safety 
monitoring board (DSMB) after mpMRI obtained 1 week post-treatment and assessment 
of treatment-related adverse events in each escalation stratile.   
 
Stopping rules for dose escalation were defined in case of dose limiting toxicity (DLT), 
significant adverse events (AEs), i.e. severe or serious drug-related AEs, changes in 
safety laboratory parameters defined as grade ≥2 according to National Cancer Institute’s 
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Common Terminology Criteria for AEs (CTCAE), unexpected or atypical MRI findings, 
or deterioration in electrocardiogram (ECG) findings. DLT was defined as specific AEs 
graded as CTCAE grade ≥3 (hypotension and venous thrombosis) or grade ≥2 
(photosensitivity related to interaction of light and drug, genito-urinary stricture/stenosis, 
rectal injury, infection and urinary retention). If ≥2 out of 3 (or ≥2 out of 6) patients at a 
particular drug and light dose combination had DLT, escalation was to be stopped and the 
previous drug and light dose was to be declared the MTD. When no further dose 
escalations were recommended by the DSMB, the recommended dose was to be 
expanded up to a maximum of 30 patients.  
 
Men were followed for a total of 12 months with serial PSA, mpMRI, physical exam, 
quality of life assessment, and adverse event recording. Light density index (LDI), 
defined as the ratio between total light-emitting length of inserted laser fibers (cm) and 
the baseline desired volume of necrosis by planimetry (cm3) of targeted prostate, was 
calculated for each patient. 
 
Volume and confluence of necrosis was assessed by post-treatment gadolinium enhanced 
mpMRI performed at 7 days and 6 months following treatment.  Volume of non-perfused 
prostate tissue was calculated by planimetry and compared to intended volume of 
necrosis..   
 
A follow-up 12-core PBx was obtained 6 months following treatment.  Men with residual 
ipsilateral PCa, meeting initial study inclusion criteria, were offered a single repeat VTP 
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procedure. The second treatment was conducted ≥ 6 weeks after the 6-month biopsy. 
Following repeat treatment, an additional 12 months of total follow-up was recorded, 
with follow-up biopsy at 6 months post-treatment. 
 
Urinary and erectile function prior to VTP, and at 1, 3, 6, and 12 months post−treatment, 
were assessed using the International Prostate Symptom Score (IPSS) and International 
Index of Erectile Function (IIEF-5) quality of life questionnaires, respectively. Quality of 
life was assessed at the same time points using the Functional Assessment of Cancer 
Therapy – Prostate (FACT-P) Questionnaire.  
 
Statistics 
All analyses were descriptive and performed for the overall cohort and individual 
treatment groups (by WST11 dose and light energy dose). Descriptive statistics were 
calculated for quantitative variables; frequency counts by category were given for 
qualitative variables.  Efficacy was analyzed by comparison of the relationship between 
drug dose/light energy dose and negative biopsies at Month 6, change from baseline in 
the proportion of viable prostate tissue as assessed by planar measurement of the area of 
ablation/non-perfused tissue using dynamic gadolinium MRI at Week 1 and Month 6, 
post-treatment changes in levels of PSA, and post-treatment changes in the IPSS, IIEF 5, 
and FACT P scores. 
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No sample size calculation was performed. The numbers of patients enrolled was based 
on the MTD determined during the study and the expansion of the MTD cohort. The 
expansion cohort was planned for up to 30 patients in total.  
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Results: 
A total of 30 men enrolled and treated in the study were included in safety and efficacy 
analysis (Table 1).  Two patients discontinued the study before the 12-month follow-up 
(1 due to withdrawal of consent and 1 because the patient moved away).  During the dose 
escalation phase, 3 patients received single fiber, 2 mg/kg WST11, 200 J/cm light and 6 
patients received 2 mg/kg WST11, 300 J/cm light (single or multifiber). Based upon 
cumulative data from PCM202 and concurrent ongoing European trials20, dose escalation 
was discontinued following the multifiber- 2mg/kg WST11 - 300 J/cm dose group by the 
DSMB and the trial sponsor, as it was felt that reproducible, confluent necrosis could be 
achieved at an optimal dosing of multiple laser fibers, 4 mg/kg WST11, and 200 J/cm 
energy, and that further escalation would risk toxicity without perceived benefit in 
efficacy.  A total of 21 patients were thus treated at the optimal dose.  
 
Evaluation of 1-week post-treatment DCE-MRI studies revealed median non-perfused 
prostate tissue was 52.3% (± 31.9) of the intended tissue ablation (Table 2), and just over 
half of the patients (56.7%) had extra-prostatic treatment extension observed. Among 21 
men receiving the optimal dosing parameters, the mean ablation effect was 64.1% (± 
25.3) of intended. Among 17 men with LDI ≥ 1, mean ablation  was 73.9% (± 14.7) of 
intended volume. For men treated with the optimal treatment parameters and LDI ≥ 1  
(n=15), the mean treatment effect was 74.3% (± 15.3) of intended.  A direct correlation 
was observed between percent ablation effect as determined by DCE-MRI and light 
energy (figure 1a) as well as LDI (figure 1b).   
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15 men had residual cancer on follow-up 6 month biopsy (Table 3).  Cancer was found 
within the treated lobe in 10 men, the untreated lobe in 4 men, and in both lobes in one 
man.  Among all men with LDI ≥ 1 (n=17), 6 men had residual cancer on biopsy, of 
whom 4 had cancer in the treated lobe.    PSA values were generally unaffected following 
VTP (figure 2), with a mean reduction of 0.11 ng/ml by 12 months.  9/11 men with 
residual cancer in the treated lobe qualified for re-treatment per trial criteria of whom 7 
opted for re-treatment of the ipsilateral lobe.  In 6/7 men, LDI≥1 was achieved.  On 6-
month biopsy following re-treatment, all 7 patients had a negative biopsy. Following re-
treatment, a total of 26 of 30 men had a negative biopsy in the treated lobe, and 22 of 30 
treated men had a negative biopsy in both lobes. 
 
Minimal, often transient, effects on urinary and sexual function, and overall quality of 
life, were observed (figure 3).  Sexual function declined by 12 months for the whole 
cohort, possibly related to the VTP procedure or secondary treatment.   Adverse events 
related to treatment were reported frequently (table 4), but no DLT, SAE, or death was 
reported.  
  
11 
 
Discussion: 
 
In summary, this first, early-phase, prospective multicenter focal therapy study to be 
undertaken in the United States demonstrated safety, tolerability and efficacy of WST-11 
VTP for soft tissue ablation in cancer-bearing prostate tissue.  Moreover, an optimal 
treatment condition (LDI≥1) was achieved in 17 of the 30 patients enrolled, across a 
range of energy exposures.  This resulted in a 74% ablation of the target volume as 
determined by a post-treatment MRI.  This conferred a cancer free status in just over 70% 
of patients treated under optimal conditions  Treatment was extremely well tolerated in 
the current study.  No SAE or dose-limiting toxicity was observed and no significant 
systemic effects were identified. Though some degree of extraprostatic treatment effect 
was observed in a subset of men there was no secondary associated SAE or irreversible 
toxicity acutely or in follow up. Overall quality of life appeared minimally affected by 
the intervention based on the patient-reported outcomes.  
 
In the study of VTP conducted by Moore, et al, similar conclusions regarding dose, 
efficacy, and safety were made10.  Among men with LDI>1, 83% were observed to have 
negative biopsy, as compared to 31.3% with LDI<1.  In that study, the overall rate of 
negative biopsy was comparable to ours when accounting for small numbers. While the 
rate of negative biopsy after one treatment is relatively low (63.3%), in our study, as 
compared to previous series of hemi-ablation using other energies, the small numbers 
preclude direct comparison.  It is possible that the learning curve, the uncertainty 
regarding potential toxicity, and the number of new operators led to a more conservative 
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or incomplete treatment.  The option of re-treating is a major advantage of ablative 
technologies, and can improve overall treatment outcomes, as it did in this case, with 
86.7% of men demonstrating negative biopsy in the treated lobe after two treatments, 
comparable to previously published reports of hemiablation2,6,21–24. 
 
It is possible that the low toxicity observed in our study was, in part, explained by the 
known mechanism of tissue destruction. WST11mediated VTP creates local tissue 
destruction through non-thermal vascular-targeted effects by a previously described 
biochemical mechanism of action triggered by the contact of drug and light 16–19.  Radical 
oxygen and nitrogen species, are created which secondarily induce permanent vascular 
thrombosis and a propagation of oxidative stress mediated cellular apoptosis into the 
tissues starting from the blood vessels 14,1718. This novel process is in direct contra-
distinction to thermal dispersion from heat-sink effects caused by perfusing blood 
vessels.  While this mechanism benefits from non-selective thrombosis of all blood 
vessels treatment zone, the adequacy of tissue destruction and the extent of apoptosis 
cannot be assessed in this study beyond the clinical endpoints utilized.  Follow-up MRI 
obtained at 7 days following treatment demonstrated both confluent and contoured non-
perfused tissue within the intended region of treatment among men receiving optimal 
drug and light dose, and adequate LDI, confirming the complete nature of vascular 
thrombosis.  
  
Another novel aspect of this type of therapy is the incorporation of treatment planning 
from preoperative imaging and the intent for ablation based on volume.  It seems likely 
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that this contributed to the low rates of extraprostatic necrosis. Planning can only be done 
if there exists a reasonably predictable correlation between dose and effect. The 
relationship between tissue ablation effects in DCE-MRI and LDI was found to be quite 
good in this regard and supports this approach. This aspect of the technique appears 
favorable, allowing for target volume to serve as the main dependent variable when 
determining the number and length of fibers required for a given case.  
 
In this study, a positive post-treatment biopsy in the treated lobe could be considered a 
failure of treatment, while a positive biopsy in the untreated lobe would likely be a failure 
of baseline staging.  Men with cancer identified to be unilateral on 12 core trans-rectal 
biopsy carry a very high likelihood of harboring bilateral malignancy 25. As pre-treatment 
mpMRI was utilized purely for treatment planning in this study, more accurate staging, 
presumably through the localization of disease by mpMRI, could likely reduce the 
numbers of positive post-treatment biopsies noted outside of the treatment zone, and 
allow better evaluation of the relationship of treatment planning and treatment failure. 
26,27 mpMRI in treatment planning has been shown to be highly sensitive in the detection 
of residual tumor following VTP. 28  
 
In addition to the method of candidate selection, additional limitations of the study design 
and interpretation include small sample size, potential for learning curve effects on quality 
of treatment given the small number of patients at individual centers, and the lack of long-
term follow-up to determine true efficacy.  Despite the limitations, the study demonstrates 
that VTP focal ablation in men with localized PCa is feasible, safe, offers potential 
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treatment of localized PCa with relatively minimal effects on quality of life.  Further 
evaluation of oncologic efficacy through larger, randomized cohort studies and through 
modified selection criteria is warranted. The results of two, phase III studies conducted in 
Europa (PCM301; NCT01310894) and Latin America (PCM304; NCT01875393) to 
confirm the efficacy and safety profile of the technique are expected in the near term.  
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Conclusions: 
 
TOOKAD® Soluble  VTP focal therapy of the prostate is feasible and appears safe in this 
limited study.  Treatment results in relatively minimal effects on quality of life in short 
term follow-up.  Treatment planning through use of MRI assessment of intended 
treatment volume, and application of LDI, can result in reproducible, confluent tissue 
destruction in the intended treatment zone. 
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Figures 
Figure 1a Relationship between Energy Delivery and Prostate Necrosis at Day 7. 
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Figure 1b. Relationship between LDI and Prostate Necrosis at Day 7 
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Figure 2:  PSA kinetics following VTP 
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Figure 3a:  Evolution of IPSS Sum of Scores for Questions 1 to 7  following VTP 
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Figure 3b: Evolution of 5-IIEF Sum of Scores following VTP 
 
 
  
24 
 
Figure 4: Evolution of FACT-P total score following VTP 
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Table 1 Baseline Characteristics  
 
 2 mg/kg 
200 J/cm 
2 mg/kg 
300 J/cm 
4 mg/kg 
200 J/cm 
 All Doses 
/ Energies 
  (N=3) (N=6) (N=21)  (N=30) 
Age (years)  (n=3) (n=6) (n=21)  (n=30) 
  Mean ± SD  58.0 ± 9.8 63.8 ± 9.2 61.4 ± 7.3  61.6 ± 7.8 
  Median  61.0 64.5 63.0  63.0 
  Range  47-66 48-74 49-73  47-74 
Race       
  Asian  0 0 1 (4.8%)  1 (3.3%) 
  Black  3 (100%) 4 (66.7%) 7 (33.3%)  14 (46.7%) 
  Caucasian  0 2 (33.3%) 12 (57.1%)  14 (46.7%) 
  Other  0 0 1 (4.8%)  1 (3.3%) 
Time since 
biopsy (months) 
 
  Mean ± SD  2.21 ± 0.35 3.3 ± 1.16 4.8 ± 2.1  4.24± 2.03 
  Median  2.1 3.5 5.0  3.8 
  Range  1.9-2.6 1.5-4.8 1.5-8.8  1.5-8.8 
Stage at 
diagnosis (TNM) 
 
     
  T1C  3 (100%) 5 (83.3%) 18 (85.7%)  26 (86.7%) 
  T1CN0MX  0 1 (16.7%) 0  1 (3.3%) 
  T2A  0 0 3 (14.3%)  3 (10%) 
Number of 
positive cores 
      
  Mean ± SD  2.0 ± 1.0 1.2 ± 0.4 1.3 ± 0.6  1.3 ± 0.7 
  Median  2.0 1.0 1.0  1.0 
  Range  1-3 1-2 1-3  1-3 
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Table 2:  Prostate Necrosis Percentage (%) as estimated by MRI at Day 7  
 2 mg/kg 
200 J/cm  
2 mg/kg 
300 J/cm 
4 mg/kg 
200 J/cm 
 All Doses 
/ Energies 
 (N=3) (N=6) (N=21)  (N=30) 
All patients (n=3) (n=6) (n=21)  (n=30) 
  Mean ± SD 46.9 ± 41.6 13.8 ± 16.3 64.1 ± 25.3  52.3 ± 31.9 
  Median 61.6 8.5 66.9  61.9 
  Range 0.0-79.1 0.0-41.8 4.8-108.9  0.0-108.9 
      
      
LDI <1 LDI ≥     1 LDI<1 (n=1) (n=6) (n=6)  (n=13) 
 Mean ± SD 0.0 ± 0.0 13.8 ± 16.3 38.5 ± 28.6  24.1 ± 25.6 
  Median 0.0 8.5 46.0  10.6 
  Range 0.0-0.0 0.0-41.8 4.8-80.0  0.0-80.0 
LDI ≥1 (n=2) (n=0) (n=15)  (n=17) 
  Mean ± SD 70.4 ± 12.4  74.3 ± 15.3  73.9 ± 14.7 
  Median 70.4  69.0  69.0 
  Range 61.6-79.1  56.5-108.9  56.5-108.9 
p-value* 0.6026  0.0168  0.0003 
Extraprostatic Necrosis (n=3) (n=6) (n=21)  (n=30) 
  Yes 
  No 
1 (33.3%) 
2 (66.7%) 
2 (33.3%) 
4 (66.7%) 
14 (66.7%) 
7 (33.3%) 
 17 (56.7%) 
13 (43.3%) 
*Wilcoxon Rank Sum Test for (LDI<1 vs. LDI>=1) 
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Table 3 
Table 3 Prostate Biopsy Results by LDI at Month 6 
 
  
2 mg/kg 2 mg/kg 4 mg/kg All Doses 
200 J/cm  300 J/cm 200 J/cm / Energies 
Biopsy Results in the treated lobe (Primary End-point) 
Overall (N=3) (N=6) (N=21) (N=30) 
    Negative 3 (100%) 3 (50.0%) 13 (61.9%) 19 (63.3%) 
 Exact 95% CI** [29.2%;100%] [11.8%;88.2%] [38.4%;81.9%] [43.9%;80.1%] 
    Positive 0 3 (50.0%) 8 (38.1%) 11 (36.7%) 
LDI<1 (n=1) (n=6) (n=6) (n=13) 
    Negative 1 (100%) 3 (50.0%) 2 (33.3%) 6 (46.2%) 
 Exact 95% CI** [2.5%;100%] [11.8%;88.2%] [4.3%;77.7%] [19.2%;74.9%] 
    Positive 0 3 (50.0%) 4 (66.7%) 7 (53.8%) 
LDI≥1 (n=2) (n=0) (n=15) (n=17) 
    Negative 2 (100%) - 11 (73.3%) 13 (76.5%) 
     Exact 95% CI** [15.8%;100%] - [44.9%;92.2%] [50.1%;93.2%] 
    Positive 0 - 4 (26.7%) 4 (23;5%) 
Biopsy Results in the whole prostate including untreated lobes (Exploratory Analysis) 
Overall (N=3) (N=6) (N=21) (N=30) 
    Negative 3 (100%) 2 (33.3%) 10 (47.6%) 15 (50.0%) 
    Positive 0 4 (66.7%) 11 (52.4%) 15 (50.0%) 
Treated Lobe Positive 0 3 (50.0%) 8 (38.1%) 11 (36.7%) 
Contralateral Positive 0 2 (33.3%*) 4 (19.0%*) 6 (20.0%*) 
LDI<1 (n=1) (N=6) (n=6) (n=13) 
    Negative 1 (100%) 2 (33.3%) 1 (16.7%) 4 (30.8%) 
    Positive 0 4 (66.7%) 5 (83.3%) 9 (69.2%) 
Treated Lobe Positive 0 (0%) 3 (50.0%) 4 (66.7%) 7 (53.8%) 
Contralateral Positive 0 (0%) 2 (33.3%*) 2 (33.3%*) 4 (46.2%*) 
LDI≥1 (n=2) (n=0) (n=15) (n=17) 
    Negative 2 (100%) - 9 (60.0%) 11 (64.7%) 
    Positive 0 - 6 (40.0%) 6 (35.3%) 
Treated Lobe Positive 0 (0%) - 4 (26.7%) 4 (23.5%) 
Contralateral Positive 0 (0%) - 2 (13.3%) 2 (11.8%) 
* Cases with bilateral cancer on biopsy can result in cumulated percentages >100% 
** For the percentage of patients with negative biopsy assessment. 
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Table 4 Number of Patients with Related AEs by Preferred Term (Safety analysis 
set) 
AE 
Overall Related to 
Study Drug 
Related to 
Study Device 
Related to 
Technical 
Procedure  
Hematuria 9 5 9 6 
Micturition urgency 9 4 9 5 
Perineal pain 8 2 8 3 
Dysuria 7 2 7 2 
Urinary retention 7 1 6 5 
Erectile dysfunction 6 4 6 5 
Pollakiuria 4 0 4 1 
Ecchymosis 4 1 4 1 
Constipation 3 2 3 1 
Anorectal 
discomfort 
3 0 3 2 
Hematospermia 3 3 3 3 
Back pain 3 1 3 2 
Urinary 
incontinence 
2 2 2 0 
Incontinence* 2 0 2 2 
Urinary tract 
infection 
2 1 2 1 
Groin pain 2 0 2 2 
Penile pain 2 1 2 1 
Headache 2 2 2 1 
Nausea 2 1 1 0 
* SOC Renal and urinary disorders. 
 
